Published 2 months ago • loading... • Updated 2 months ago

They may be ‘miracle’ drugs, but obesity meds call for a team approach

Summary by STAT

The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single physician to handle.

5 Articles

All

Left

Center

Right

STAT

They may be ‘miracle’ drugs, but obesity meds call for a team approach

The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single physician to handle.

2 months ago·Boston, United States

Read Full Article

elblog.pl

Major Pharma Battle! Merck Intensifies Obesity Drug Race

Not everything was bright and shiny for Viking Therapeutics as 2024 came to a close. The company’s stock took a 24% tumble in December, closely tied to moves made by a formidable competitor, Merck, which is steering into the potentially lucrative obesity drug market. The Competitor: Merck’s Bold Move In a strategic maneuver, Merck partnered with Chinese biotech Hansoh Pharma to develop an investigational obesity medication. This drug, HS-10535, …

2 months ago

Read Full Article

ramaonhealthcare.com

Lotte Bjerre Knudsen: The Scientist Who Drove GLP-1 Drugs For Obesity and Alzheimer's – RamaOnHealthcare

The Chief Scientific Advisor at Novo Nordisk, Lotte Bjerre Knudsen, was the key force who pushed hard to develop GLP-1 drugs for treating obesity and subsequently for Alzheimer’s. She was recently recognized by the 2024 Lasker Medical Research Award, and the 2024 AAAS Bhaumik Breakthrough of the Year Award. That recognition is richly deserved, since [...]

2 months ago

Read Full Article

Bioethics.com

Use of diabetes and anti-obesity drugs surges nationwide

(Axios) – The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The data, which shows double-digit growth in 23 states, offers a snapshot of the sustained growth in demand across the U.S. for the drugs hailed as game-changers in the fight against obesity. (Read More)

2 months ago

Read Full Article

Dataemia

Ozempic’s logistical challenges have doctors look to team approach

Life was improving for Carlos Campos, 72, after starting Ozempic for his type 2 diabetes. When Medicare stopped covering the drug, his blood sugar levels rose, but his diabetes educator helped him access the medication through a patient assistance program. The rise of GLP-1 drugs like Ozempic presents challenges that require a team approach to ensure access and proper treatment. However, barriers to access, affordability, and discontinuation sti…

2 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year